Eisai H3B-6527-G000-101 for HCC or ICC - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find the maximum dose of the study drug that is safe for patients to take. We also want to learn if the study drug can make the size of your tumor smaller.
Advanced hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)
Who Can Participate in the Study?
- Have advanced hepatocellular carcinoma or intrahepatic cholangiocarcinoma
- Have had treatment with sorafenib if you have HCC or have had cisplatin/oxaliplatin if you have ICC
What is Involved?
If you choose to join this study, you will:
- Take the study drug, called H3B-6527, by mouth every day in 21 day cycles
- Continue to take the study drug as long as the study doctors thinks it is safe